{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:22:46Z","timestamp":1740147766073,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"ricerca corrente 2023"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s11739-024-03635-2","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T05:02:08Z","timestamp":1716008528000},"page":"1577-1583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bleeding and thrombotic events and intensity of heparin therapy in the two first waves of COVID-19"],"prefix":"10.1007","volume":"19","author":[{"given":"Raffaella","family":"Rossio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Tettamanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia Antonella","family":"Galbussera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-7624","authenticated-orcid":false,"given":"Roberta","family":"Gualtierotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Giachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Torri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Montano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Ludovica","family":"Fracanzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Bandera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Nobili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the COVID-19 Network","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"key":"3635_CR1","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3324\/haematol.2020.262634","volume":"106","author":"F Peyvandi","year":"2021","unstructured":"Peyvandi F, Artoni A, Novembrino C et al (2021) Hemostatic alterations in COVID-19. Haematologica 106:1472\u20131475. https:\/\/doi.org\/10.3324\/haematol.2020.262634","journal-title":"Haematologica"},{"key":"3635_CR2","doi-asserted-by":"publisher","first-page":"m1091","DOI":"10.1136\/bmj.m1091","volume":"368","author":"T Chen","year":"2020","unstructured":"Chen T, Wu D, Chen H et al (2020) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368:m1091","journal-title":"BMJ"},{"key":"3635_CR3","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jth.14817","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang N, Bai H, Chen X et al (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18:1094\u20131099. https:\/\/doi.org\/10.1111\/jth.14817","journal-title":"J Thromb Haemost"},{"key":"3635_CR4","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1111\/jth.15310","volume":"19","author":"R Halaby","year":"2021","unstructured":"Halaby R, Cuker A, Yui J et al (2021) Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study. J Thromb Haemost 19:1533\u20131545. https:\/\/doi.org\/10.1111\/jth.15310","journal-title":"J Thromb Haemost"},{"key":"3635_CR5","volume-title":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]","author":"National Institutes of Health","year":"2021","unstructured":"National Institutes of Health (2021) Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. National Institutes of Health, Bethesda (MD)"},{"key":"3635_CR6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s11739-020-02585-9","volume":"16","author":"I Martinelli","year":"2021","unstructured":"Martinelli I, Ciavarella A, Abbattista M et al (2021) Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19. Intern Emerg Med 16:1223\u20131229. https:\/\/doi.org\/10.1007\/s11739-020-02585-9","journal-title":"Intern Emerg Med"},{"key":"3635_CR7","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1002\/jcph.1749","volume":"60","author":"J Ferguson","year":"2020","unstructured":"Ferguson J, Volk S, Vondracek T et al (2020) Anticoagulation and Mortality in Critically Ill Patients With Respiratory Failure From SARS-CoV-2: A Retrospective Cohort Study. J Clin Pharmacol 60:1411\u20131415. https:\/\/doi.org\/10.1002\/jcph.1749","journal-title":"J Clin Pharmacol"},{"key":"3635_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/1358863X20932640","volume":"25","author":"ME Colling","year":"2020","unstructured":"Colling ME, Kanthi Y (2020) COVID-19-associated coagulopathy: An exploration of mechanisms. Vasc Med 25:471\u2013478. https:\/\/doi.org\/10.1177\/1358863X20932640","journal-title":"Vasc Med"},{"key":"3635_CR9","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.cmi.2020.06.028","volume":"26","author":"A Bandera","year":"2020","unstructured":"Bandera A, Aliberti S, Gualtierotti R et al (2020) COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemia. Clin Microbiol Infect 26:1576\u20131578. https:\/\/doi.org\/10.1016\/j.cmi.2020.06.028","journal-title":"Clin Microbiol Infect"},{"key":"3635_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Anger\u00e5s U, Bergqvist D et al (2010) Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8:202\u2013204. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03678","journal-title":"J Thromb Haemost"},{"key":"3635_CR11","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119\u20132126. https:\/\/doi.org\/10.1111\/jth.13140","journal-title":"J Thromb Haemost"},{"key":"3635_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","volume":"191","author":"FA Klok","year":"2020","unstructured":"Klok FA, Kruip MJHA, van der Meer NJM et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145\u2013147. https:\/\/doi.org\/10.1016\/j.thromres.2020.04.013","journal-title":"Thromb Res"},{"key":"3635_CR13","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1055\/a-1878-6806","volume":"6","author":"D Poli","year":"2022","unstructured":"Poli D, Antonucci E, Ageno W et al (2022) Thromboembolic Complications in COVID-19 Patients Hospitalized in Italian Ordinary Wards: Data from the Multicenter Observational START-COVID Register. TH Open 6:e251\u2013e256","journal-title":"TH Open"},{"key":"3635_CR14","doi-asserted-by":"publisher","first-page":"e0280247","DOI":"10.1371\/journal.pone.0280247","volume":"18","author":"F Pieralli","year":"2023","unstructured":"Pieralli F, Pomero F, Corbo L et al (2023) Incidence of lower limb deep vein thrombosis in patients with COVID-19 pneumonia through different waves of SARS-CoV-2 pandemic: A multicenter prospective study. PLoS ONE 18:e0280247. https:\/\/doi.org\/10.1371\/journal.pone.0280247","journal-title":"PLoS ONE"},{"issue":"377","key":"3635_CR15","doi-asserted-by":"publisher","first-page":"e069590","DOI":"10.1136\/bmj-2021-069590","volume":"6","author":"I Katsoularis","year":"2022","unstructured":"Katsoularis I, Fonseca-Rodr\u00edguez O, Farrington P, at al, (2022) Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ 6(377):e069590. https:\/\/doi.org\/10.1136\/bmj-2021-069590","journal-title":"BMJ"},{"key":"3635_CR16","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jama.2020.17023","volume":"324","author":"JAC Sterne","year":"2020","unstructured":"Group WHOREAfC-TW, Sterne JAC, Murthy S et al (2020) Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324:1330\u20131341. https:\/\/doi.org\/10.1001\/jama.2020.17023","journal-title":"JAMA"},{"key":"3635_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.thromres.2020.12.019","volume":"199","author":"FHJ Kaptein","year":"2021","unstructured":"Kaptein FHJ, Stals MAM, Grootenboers M et al (2021) Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. Thromb Res 199:143\u2013148","journal-title":"Thromb Res"},{"key":"3635_CR18","doi-asserted-by":"publisher","first-page":"102031","DOI":"10.1016\/j.eclinm.2023.102031","volume":"60","author":"S Zuily","year":"2023","unstructured":"Zuily S, Lef\u00e8vre B, Sanchez OCOVI-DOSE, investigators. et al (2023) Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial. EClinicalMedicine 60:102031. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102031","journal-title":"EClinicalMedicine"},{"key":"3635_CR19","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1001\/jama.2020.4683","volume":"323","author":"G Onder","year":"2020","unstructured":"Onder G, Rezza G, Brusaferro S (2020) Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA J Am Med Assoc 323:1775\u20131776. https:\/\/doi.org\/10.1001\/jama.2020.4683","journal-title":"JAMA J Am Med Assoc"},{"key":"3635_CR20","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s11739-021-02742-8","volume":"16","author":"E Corradini","year":"2021","unstructured":"Corradini E, Ventura P, Ageno W et al (2021) Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). Intern Emerg Med 16:1005\u20131015. https:\/\/doi.org\/10.1007\/s11739-021-02742-8","journal-title":"Intern Emerg Med"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-024-03635-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-024-03635-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-024-03635-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T12:25:12Z","timestamp":1726662312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-024-03635-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["3635"],"URL":"https:\/\/doi.org\/10.1007\/s11739-024-03635-2","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"type":"print","value":"1828-0447"},{"type":"electronic","value":"1970-9366"}],"subject":[],"published":{"date-parts":[[2024,5,18]]},"assertion":[{"value":"31 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.G. has received honoraria for participating as a speaker in education meetings organized by Pfizer, Novo Nordisk, Sobi, Takeda, and Roche and is a member of the scientific advisory boards of Bayer, Sobi, Roche, and Pfizer. F.P. has received honoraria for participating as a speaker in education meetings and symposia organized by Takeda and Spark. She is a consultant\/member of the advisory boards for CSL Behring, Biomarin, Roche, Sanofi, and Sobi. The remaining authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Ospedale Maggiore Policlinico.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors state that this research was conducted in accordance with the Helsinki Declaration as revised in 2008.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}}]}}